Stock Rating Report for ACHN
|
|
Stock Information
| Ticker |
ACHN |
| Company Name |
Achillion Pharmaceuticals, Inc |
| Current Price |
$10.38 |
| Previous Close |
$10.38 |
| Industry |
Biotechnology |
| Sector |
HEALTHCARE |
| Long Stop Loss |
Members Only |
| Short Stop Loss |
Members Only |
| Expected Move |
Members Only |
| Optionable? |
Yes
|
StockProphet Ratings
Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.
Sector Risks
Chart
We use technical analysis and fundamental analysis to recommend ratings for thousands of stocks. If you had a subscription, this space would show our 3 year history of trades for ACHN. However, we only show it to our subscribers.
We update our ratings and stop losses EVERY WEEK.
Don't miss out on what we recommend for Achillion Pharmaceuticals, Inc next week. Sign up today and start making money!
Demand Fundamentals
|
Demand Technicals
Company Profile
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. The company focuses on the development of antivirals for the treatment of chronic hepatitis C- and the development of antibacterials for the treatment of resistant bacterial infections. Its drug candidates for the treatment of chronic HCV include ACH-1625, a protease inhibitor, which is in phase IIa clinical trial for the treatment of chronic HCV- ACH-2684, a pangenotypic protease inhibitor, which is in phase I clinical trial for the treatment of chronic HCV infection- and NS5A inhibitors for the treatment of chronic HCV infection, including ACH-2928, which is to enter a phase I clinical trial, as well as various additional NS5A inhibitors in preclinical development. Its pipeline of product candidates also includes ACH-702 and ACH-2881 for drug resistant bacterial infections- elvucitabine for HIV infection- and ACH-1095 for HCV infection. The company was founded in 1998 and is based in New Haven, Connecticut.
|
Latest News
| Tue, 07 Feb 2012 23:03:03 GMT | Nasdaq stocks posting largest percentage decreases | | Tue, 07 Feb 2012 21:51:23 GMT | Tuesday?s biggest gaining and declining stocks | | Tue, 07 Feb 2012 19:19:28 GMT | BofA Downgrade Sends Achillion Plunging | | Tue, 07 Feb 2012 18:21:37 GMT | Nasdaq stocks posting largest percentage decreases | | Tue, 07 Feb 2012 17:11:28 GMT | On The Fly: Mid-Day Wrap | | Tue, 07 Feb 2012 15:06:27 GMT | Trading Biotech In Pairs: A Better Way To Hedge | | Tue, 07 Feb 2012 12:19:37 GMT | Achillion downgraded at BofA/Merrill | | Mon, 06 Feb 2012 13:56:00 GMT | Emerald Holds Annual Groundhog Day Investment Forum | | Fri, 03 Feb 2012 14:30:39 GMT | Pre-market top 5 losers | | Fri, 03 Feb 2012 12:00:00 GMT | Achillion Announces Executive Promotion | | Fri, 03 Feb 2012 01:24:08 GMT | Gilead Gains on Positive Data From Experimental Hepatitis C Drug | | Wed, 01 Feb 2012 23:02:27 GMT | 9 Biotechs Gaining Analyst Attention | | Wed, 01 Feb 2012 05:01:51 GMT | Achillion, Idenix could miss hep-C merger bonanza | | Mon, 30 Jan 2012 14:53:13 GMT | Has Gilead Sciences Become the Perfect Stock? | | Fri, 27 Jan 2012 12:00:00 GMT | Biotech Stock Mailbag: Vical, Hep C Drugs | | Thu, 26 Jan 2012 19:48:57 GMT | Major Wave of Biotech Mergers Expected | | Thu, 26 Jan 2012 09:31:00 GMT | Hedge Funds Are Buying Up These 20 Healthcare Stocks | | Wed, 25 Jan 2012 19:28:50 GMT | Biotech Investors Confident: Industry Sees Big VC Spending in 2011 | | Wed, 25 Jan 2012 13:55:00 GMT | Top Stock Alerts for Day Traders: Atmel, R.R. Donnelley & Sons, BioLineRx, Achillion Pharmaceuticals, Windstream and Rare Element Resources | | Wed, 25 Jan 2012 13:36:40 GMT | Company News for January 25, 2012 | News provided by Yahoo! Finance |
|
|
|
|
